EF
OVID icon

Empowered Funds’s Ovid Therapeutics OVID Stock Holding History

Empowered Funds’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Hold
91,234
– – ﹤0.01% 1937
2026
Q1 		$203K Buy
+91,234
New +$163K ﹤0.01% 2019
2025
Q4 		– Sell
-91,234
Closed -$119K – 1642
2025
Q3 		$119K Hold
91,234
– – ﹤0.01% 1782
2025
Q2 		$30.1K Hold
91,234
– – ﹤0.01% 1742
2025
Q1 		$28.5K Sell
91,234
-47,181
-34% -$29K ﹤0.01% 1609
2024
Q4 		$129K Sell
138,415
-6,925
-5% -$7.75K ﹤0.01% 1558
2024
Q3 		$172K Buy
145,340
+7,370
+5% +$7.7K ﹤0.01% 1340
2024
Q2 		$106K Buy
137,970
+9,900
+8% +$27.6K ﹤0.01% 1340
2024
Q1 		$391K Buy
128,070
+9,625
+8% +$32.2K 0.01% 1134
2023
Q4 		$381K Buy
118,445
+10,645
+10% +$36.4K 0.01% 1048
2023
Q3 		$414K Buy
107,800
+8,848
+9% +$31.8K 0.01% 973
2023
Q2 		$325K Buy
+98,952
New +$336K 0.01% 936

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Empowered Funds's OVID Position: Q2 2026 in Review

Empowered Funds held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 91,234 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #1937.

Empowered Funds first reported a position in OVID in Q2 2023 and has held it in 12 quarters since. The position peaked at $414K in Q3 2023. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Empowered Funds held 91,234 shares of Ovid Therapeutics worth $245K as of Q2 2026.
  • Empowered Funds left its Ovid Therapeutics share count unchanged in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1937 holding.
  • Empowered Funds first reported a position in Ovid Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Empowered Funds's Ovid Therapeutics position peaked at $414K in Q3 2023.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.